Full project title: Novel plasma Human Papillomavirus DNA assay as a predictor of residual disease after chemo-radiotherapy for locally advanced head and neck cancer
Tag: Predictive tests
As well as alcohol and tobacco, the human papilloma virus (HPV) is a known risk factor in head and neck cancer. HPV-positive head and neck cancer has been rising over the past 30 years and is set to continue, with a predicted increase of 230% in coming years.
In patients with HPV-positive head and neck cancer, it is not always clear from scans (PET-CT) if treatment with chemo-radiotherapy has been totally successful in clearing the cancer. In these cases, patients frequently undergo unnecessary neck dissection and repeated biopsies to make sure there is no disease remaining, also called residual disease. This causes significant morbidity.
Dr Shree Bhide
Dr Jen Lee
Length of project:
The Institute of Cancer Research
Get in touch
Oracle Cancer Trust is a registered charity in England and Wales (1142037). A company limited by guarantee. Registered company in England and Wales (7125497). Registered address: 10 Parsons Green House, 27 Parsons Green Lane, London SW6 4HH.